NCT00644696View on ClinicalTrials.gov

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Neuroblastoma
Interventions
DRUG

Irinotecan and Bortezomib

Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day

Trial Locations (1)

48109

The University of Michigan Comprehensive Cancer Center, Ann Arbor

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER